Proton Pump

Related Products

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on theQ cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a protonconcentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences inbuffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

Proton Pump Related Products (177)
Antibodies (1)

By Effects:	Inhibitors (153) Agonists (3) Controls (3) Antagonists (3) Activator (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-W699907

Pantoprazole sulfide-d₈
Pantoprazole sulfide-d₈ is the deuterium labeled Pantoprazole sulfide (HY-W016033). Pantoprazole sulfide is a metabolite of Pantoprazole (HY-17507), which is a proton-pump inhibitor.

HY-13662R

Lansoprazole (Standard)	Inhibitor
Lansoprazole (Standard) is the analytical standard of Lansoprazole. This product is intended for research and analytical applications. Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).

HY-17507S1

Pantoprazole-d₃	Inhibitor
Pantoprazole-d₃ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142).

HY-125707

Concanamycin B	Inhibitor
Concanamycin B is a macrolide antibiotic, which can inhibit the cavitation type H+-ATPases, and the IC₅₀ value is 5 nM.

HY-17021S2

Esomeprazole-d₃ potassium	Inhibitor
Esomeprazole-d₃ potassium is deuterated labeled Esomeprazole (HY-17021). Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H⁺, K⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.

HY-123662

AGN-201904Z	Inhibitor
AGN-201904Z is a compound that inhibits gastric acid secretion and is a new type of proton pump inhibitor that can produce more significant and lasting acid suppression effects than esomeprazole.

HY-W008614S

Lansoprazole sulfone-d₄	Inhibitor
Lansoprazole sulfone (AG-1813)-d₄ is the deuterium labeled Lansoprazole sulfone (HY-W008614). Lansoprazole sulfone, Lansoprazole (HY-13662) metabolite, is a H⁺, K⁺-ATPase inhibitor. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease.

HY-101646

Saviprazole	Inhibitor
Saviprazole (HOE-731) is a H⁺,K⁺-ATPase inhibitor. Saviprazole inhibits gastric acid secretion. Saviprazole inhibits histamine- and dbcAMP-stimulated [¹⁴C]aminopyrine uptake, dbcAMP-induced oxygen consumption. Saviprazole can be used in research related to gastrointestinal diseases, such as gastric ulcers and acid reflux.

HY-B0656AS2

Rabeprazole-d₄ potassium	Inhibitor
Rabeprazole-d₄ potassium is deuterated labeled Rabeprazole potassium. Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an b>IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux.

HY-B0113S1

Omeprazole-d₃-1	Inhibitor
Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole-1 (H 16868) is an orally active H⁺,K⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole-1 competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole-1 inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole-1 inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole-1 alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole-1 aslo has neuroprotective and antibacterial effects.

HY-W709055

Pantoprazole sulfone-d₆ (major)
Pantoprazole sulfone-d₆ (major) is the deuterium labeled Pantoprazole sulfone (HY-117225). Pantoprazole sulfone is a metabolite of the gastric H+/K+ ATPase pump inhibitor Pantoprazole (HY-17507).

HY-162264

Tubulin polymerization/V-ATPase-IN-1	Inhibitor
Tubulin polymerization/V-ATPase-IN-1 (compound F10) is a Tubulin polymerization/V-ATPase inhibitor. Tubulin polymerization/V-ATPase-IN-1 shows robust antiproliferation activity against four human cancer cell lines, and exerts antiproliferative activity by inhibiting tubulin and V-ATPase. Tubulin polymerization/V-ATPase-IN-1 induces immunogenic cell death in addition to apoptosis, and inhibits tumor growth in an RM-1 homograft model with enhanced T lymphocyte infiltration.

HY-W719463

Rabeprazole sulfide-d₄
Rabeprazole sulfide-d₄ is the deuterium labeled Rabeprazole Sulfide (HY-W003467). Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H+/K+)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment.

HY-177424

Eprazole trisulfide dimer	Inhibitor
Eprazole trisulfide dimer is a trisulfide dimer of Ilaprazole (HY-101664), an orally active proton pump inhibitor that irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with an IC₅₀ of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Eprazole trisulfide dimer can be utilized in research on gastric ulcers.

HY-A0213

Tiludronate	Inhibitor
Tiludronate (Tiludronic Acid), an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.

HY-101664S

Ilaprazole-d₃	Inhibitor
Ilaprazole-d₃ (IY-81149-d₃) is deuterium-labeled Ilaprazole (HY-101664).

HY-163696A

HV1-IN-1 hydrochloride
HV1-IN-1 hydrochloride is an inhibitor of the human voltage-gated proton channel (hHV1). HV1-IN-1 hydrochloride works by binding to the VSD of the HV1 channel. The VSD is a component of the HV1 channel that is responsible for detecting changes in membrane potential and triggering the opening of the channel. HV1-IN-1 hydrochloride can be used in the study of cancer, neuroinflammation and immune response.

HY-17623S

Tegoprazan-d₆
Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H⁺/K⁺-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases.

HY-400540A

Padoprazanum fumarate	Inhibitor
Padoprazanum (Padoprazan) fumarate is a Proton Pump inhibitor.

HY-123370

FR-167356
FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC₅₀ values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Proton Pump

Proton Pump

Proton Pump Related Products (177)

Antibodies (1)

Proton Pump Related Products (177):